Pharma stocks have been on quite a nice run over the past year. A number of new catalysts have revitalized this sector, which I’m going to dive into with a few of these picks. Whether we’re talking about innovative new drugs aimed at weight loss and other cancers or ailments, or simply greater operating efficiency and returns on capital, there are reasons why many investors continue to scour this sector for growth.
It hasn’t always been like this. In fact, many top big pharma names have struggled to provide meaningful growth over the past decade. Outside of certain Covid vaccine catalysts, and some mergers and acquisitions activity in the space, it’s been relatively slow going for longer-term investors. However, the tide does appear to be changing, and these three stocks do look well-positioned to continue to capitalize on certain growth catalysts in this sector.
This post originally appeared at 24/7 Wall St.